Galena Biopharma to Present at the Sachs Associates 16th Annual Biotech in Europe Forum
September 20 2016 - 7:05AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of hematology
and oncology therapeutics that address unmet medical needs, today
announced that Mark W. Schwartz, Ph.D., President and Chief
Executive Officer will present a corporate update at the Sachs
Associates 16th Annual Biotech in Europe Forum. The presentation
will take place on Wednesday, September 28, 2016 at 10:15 a.m.
local time at the Congress Center Basel in Basel, Switzerland.
The presentation will be webcast and available on
the Investors section of the Company's website at
http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical
company committed to the development and commercialization of
hematology and oncology therapeutics that address unmet medical
needs. Galena’s pipeline consists of multiple mid-to-late-stage
clinical assets led by its hematology asset, GALE-401, and novel
cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and
GALE-301/GALE-302. For more information, visit
www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024